CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0129-000 |
|---|---|
| Brand Name | Vizimpro |
| Generic Name | Dacomitinib |
| Strength | 15 mg, 30 mg & 45 mg |
| Tumour Type | Lung |
| Indication | Non-Small Cell Lung Cancer |
| Funding Request | For the first-line treatment of patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. |
| Review Status | Complete |
| Pre Noc Submission | Yes |
| NOC Date | February 26, 2019 |
| Manufacturer | Pfizer Canada Inc. |
| Sponsor | Pfizer Canada Inc. |
| Submission Date | September 19, 2018 |
| Submission Deemed Complete | October 3, 2018 |
| Submission Type | Initial |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | October 3, 2018 |
| Check-point meeting | December 4, 2018 |
| pERC Meeting | March 21, 2019 |
| Initial Recommendation Issued | April 4, 2019 |
| Feedback Deadline ‡ | April 18, 2019 |
| pERC Reconsideration Meeting | May 16, 2019 |
| Final Recommendation Issued | May 31, 2019 |
| Notification to Implement Issued | June 17, 2019 |
| Therapeutic Area | Non-Small Cell Lung Cancer |
| Recommendation Type | Reimburse with clinical criteria and/or conditions |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
